title: Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS.
abstract: Parenteral drug abusers are the second largest group at risk for developing AIDS (25% of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984-1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV-1) infection (but 49% of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20%; 81% of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7% vs. 0.8%, P less than .05) and antibody (0 vs. 21.4%, P less than .01) and HBsAg (15.1% vs. 5.1%, P less than .05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.
authors.affiliation: Rockefeller University, New York, NY 10021.
authors.forename: M J
authors.initials: MJ
authors.lastname: Kreek
authors.forename: D C
authors.initials: DC
authors.lastname: Des Jarlais
authors.forename: C L
authors.initials: CL
authors.lastname: Trepo
authors.forename: D M
authors.initials: DM
authors.lastname: Novick
authors.forename: A
authors.initials: A
authors.lastname: Abdul-Quader
authors.forename: J
authors.initials: J
authors.lastname: Raghunath
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000956:Antigens, Viral / Q000097:blood; D006679:HIV Seropositivity / Q000150:complications; D015497:HIV-1 / Q000276:immunology; D006508:Hepatitis Antibodies / Q000097:blood; D006509:Hepatitis B / Q000150:complications*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D003699:Hepatitis D / Q000150:complications*; D003698:Hepatitis Delta Virus / Q000276:immunology*; D035923:Hepatitis delta Antigens; D006801:Humans; D007407:Interviews as Topic; D012307:Risk Factors; D015819:Substance Abuse, Intravenous / Q000150:complications*
chemical_list: D000956:Antigens, Viral; D006508:Hepatitis Antibodies; D006514:Hepatitis B Surface Antigens; D035923:Hepatitis delta Antigens; C442244:hepatitis delta virus large antigen